Y-mAbs Therapeutics, Inc. (YMAB)
After hours:
| Previous Close | 14.84 |
| Open | 14.92 |
| Bid | 14.67 x 400 |
| Ask | 14.76 x 400 |
| Day's Range | 14.35 - 15.13 |
| 52 Week Range | 4.60 - 20.90 |
| Volume | |
| Avg. Volume | 391,465 |
| Market Cap | 643.961M |
| Beta (5Y Monthly) | 0.76 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.49 |
| Earnings Date | May 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.43 |
GlobeNewswireY-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024
The Company will host a conference call and webcast on Wednesday, May 8, 2024 at 8:00 a.m. ETNEW YORK, April 26, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended March 31, 2024, on Tuesday, May 7, 2024, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Wednesday, May 8, 2024, a
- GlobeNewswire
Y-mAbs to Present at 2024 ASCO Annual Meeting
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the acceptance of four abstracts at the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, IL. “This year’s ASCO p
Simply Wall St.Y-mAbs Therapeutics (NASDAQ:YMAB) rises 9.6% this week, taking one-year gains to 161%
Unfortunately, investing is risky - companies can and do go bankrupt. But when you pick a company that is really...
